Investigation: Portsmouth neighbors concerned about Nansemond Indian group home
PORTSMOUTH, Va. (WAVY) — The reactions to the new owner of a single-family home in the established Pinehurst neighborhood range somewhere from 'not in my backyard' to 'I don't have a problem with it.'
The property on Wake Forest Road was purchased last September by Fishing Point, the healthcare affiliate of the Nansemond Indian Nation, but it's unclear what it will be doing at the home.
Pinehurst is an established Churchland neighborhood off High Street, where the homes date back to the 1950s. And what's also been around for decades — the kind of controversy surrounding the new neighbor.
Previously: Nansemond tribe brings medical and mental health care to underserved communities
'This is a nice neighborhood,' said Andrew Jenkins, who lives across Wake Forest from the Fishing Point property and has children who play in the neighborhood. 'I'm not saying they're bad, but why throw a stick in the balloon and pop it for no reason.'
Fishing Point already has existing operations on London Boulevard in Portsmouth and Forehand Drive in the Deep Creek section of Chesapeake. Neighbors say they've heard various versions of how the home on Wake Forest Road will be used.
10 On Your Side knocked on the door during a visit in April. A woman inside repeatedly responded, 'I'm not at liberty to say,' when we asked about how the property would be used and who would live there.
A Fishing Point van was parked in the driveway emblazoned with the message 'Transformative Mental Health Care for All.' Some neighbors wonder if that means recovery from alcohol and substance abuse.
'I get it,' Jenkins said. 'They're trying to better themselves. But why do it in a residential neighborhood?'
Next door, a different perspective.
'([I have no problem] with them, no sir,' said Wayne Brown, who recently moved to the neighborhood from Texas. 'Those people need a place.'
City records show the 1951 Cape Cod home has 3,600 square feet of living space. Fishing Point bought it last September for $550,000, more than twice what it sold for ($260,000) just three years earlier. They've been pouring money into it ever since.
'I noticed they did a lot of repairs and it seemed like an endless amount of improvements,' Brown said. 'They made the place look very nice.'
'It's zoned residential,' said Portsmouth Deputy City Attorney Jeff Miller, outside last week's meeting of the Board of Zoning Appeals.
Fishing Point has a current case before the BZA, and they were on the docket last week but their main attorney didn't show and it was continued to May 28. 'They had not complied with the zoning requirements to operate their group home,' Miller said.
And despite the well-manicured lawn, the case gets into the weeds legally when it comes to the definition of a group home 'which under state law is not treated as a business. It's treated almost as a single-family residence,' Miller said.
Miller said with the proper permit and then a business license, Fishing Point can operate its home in the Portsmouth neighborhood, even if they're not welcome.
'End of the day, nobody wants this,' Jenkins said. 'When you work that hard to buy a house and the next thing you know things are popping up in the neighborhood. This has nothing to do with the neighborhood at all.'
Other neighbors told us off-camera: 'I'm not comfortable with this with all the kids in the neighborhood' and 'I understand you're doing a story, but I don't want any retribution.'
Again, Brown doesn't see a problem.
'I'd rather they have a nice looking place to keep them than some slum, he said.
10 On Your Side reached out to the attorney for Fishing Point and its media contact, but got no response. If Fishing Point gets the necessary permit for the group home, and then a business license, it looks like they are on Wake Forest Road to stay.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
3 hours ago
- Forbes
Is Elon Musk's Ketamine Use Encouraging Dangerous Self-Medication?
Elon Musk's candid admission about using ketamine for depression made headlines. So did Naomi Campbell's extensive vitamin regimen and Gwyneth Paltrow's jade eggs. And these are just the careinfluencers you've heard of. In the age of social media, celebrities and patients alike aren't just endorsing products — they're dispensing medical advice, often with zero qualifications. Welcome to the era of 'carefluencers' — a growing class of influencers who peddle wellness tips, off-label drug use and even prescription workarounds to millions of followers. And this is not surprising:, a new Healthline/YouGov survey shows Americans of all ages are increasingly turning to social media for health information — and skipping preventive care. But behind the slick posts and quick fixes lies a dangerous truth: when trust in science erodes, real people pay the price—with misdiagnoses, harmful self-medication, and preventable suffering. Celebrities like Musk or longevity biohacker Bryan Johnson wield immense influence. A single tweet can send ketamine clinic inquiries soaring or spark a run on unproven biohacks. But there's a critical difference between medical treatment and recreational experimentation: Healthcare is increasingly consumer-driven — fueled by viral demand for everything from Ozempic to off-label ADHD meds — and physicians are feeling the pressure from the requests. Patients now rate physicians like Uber drivers, and nobody wants a bad review, especially from a VIP. It's not too difficult to imagine a celebrity demanding Adderall for focus or ketamine for mood boosts. If the doctor says no, they'll find someone who says yes. Money becomes power, and without clinical oversight, that power enables harmful behaviors. The result? A perfect storm where hyperagency — the celebrity belief that rules simply don't apply — collides with narcissistic influence and unchecked social capital. These forces distort reality: patient demands override medical judgment, while unvetted advice from carefluencers (who face zero accountability for their 'recommendations') fuels prescription abuse epidemics. It's a system where fame trumps science, and the casualties are evidence-based medicine itself. The dangers of carefluencers—from Musk's ketamine takes to viral 'biohacks'—reveal a hard truth: celebrity endorsements work for fashion trends, not healthcare. When lives are at stake, trust belongs to clinicians, not unqualified influencers. Unlike a bad outfit choice, the consequences of misguided medical advice can't be returned or refunded.
Health Line
5 hours ago
- Health Line
Is Bulimia Different from Binge Eating?
Bulimia nervosa and binge eating disorder (BED) are both serious eating disorders characterized by episodes of consuming large amounts of food, a behavior called binge eating. The primary difference lies in the aftermath: people with bulimia engage in compensatory behaviors, such as vomiting or excessive exercise, to prevent weight gain, whereas those with BED don't often use such measures. Whether you suspect you have BED, bulimia, or a different eating disorder, it's a good idea to seek help. These disorders are treatable. The first step is to speak with a healthcare professional. Key similarities Despite their differences, bulimia and BED share several characteristics: Binge eating episodes: Both disorders involve consuming unusually large quantities of food in a specific period of time, accompanied by a sense of loss of control. Emotional distress: People with these disorders often experience feelings of shame, guilt, or depression following binge episodes. Triggers: Stress, negative emotions, or restrictive dieting can precipitate binge eating in both conditions. Co-occurring mental health conditions: Both disorders are associated with higher rates of anxiety, depression, and other psychological conditions. Co-occurring physical health conditions: Both BED and binge eating can lead to physical health issues. Treatment: Both BED and bulimia are treatable. Therapy, lifestyle changes, and — in some cases — medications can help improve your symptoms. Learn more about therapy for eating disorder treatment. Because both BED and bulimia involve binge eating, many people confuse the two. A trained healthcare professional can help you find the correct eating disorder diagnosis and treat you accordingly. Key differences At first glance, bulimia and BED are quite similar. Understanding the distinctions between bulimia and BED is important for getting the right treatment. Here are some key differences: Compensatory behaviors: Unlike BED, bulimia involves trying to counteract the effects of binge eating, like self-induced vomiting, laxative misuse, fasting, or excessive exercise. Prevalence: BED is more common than bulimia nervosa. In the US, about 1% of people will have bulimia at some point in their lives. For BED, that number rises to 2.8%. Body weight: People with BED are more likely to be overweight or obese. People with bulimia may fall in a more 'normal' weight range, although this isn't always the case. Body image: People with bulimia are more likely to have body image disturbances and an obsession with weight loss. However, people with BED may also have difficulties with body image. Frequency: While both disorders involve binge eating, the frequencies can differ. BED is diagnosed if episodes occur at least once a week for three months without compensatory behaviors. Health consequences: Bulimia can lead to electrolyte imbalances, gastrointestinal issues, and dental problems due to purging. BED is associated with obesity-related conditions like type 2 diabetes, hypertension, and cardiovascular disease. If you think you have BED or bulimia, a healthcare professional can help you find a diagnosis and get the treatment you need. When to contact a healthcare professional If you or someone you know exhibits signs of bulimia or BED, it's essential to seek professional help. Early intervention can prevent complications and improve outcomes. Consider reaching out to a healthcare professional if you experience any of the following symptoms: Frequent episodes of eating large amounts of food in a short time Engaging in purging behaviors or excessive exercise after eating Feelings of distress, shame, or guilt related to eating habits Preoccupation with body weight or shape A medical professional specializing in can provide a comprehensive assessment and recommend appropriate treatment options.
CNBC
5 hours ago
- CNBC
26. Iambic Therapeutics
Founders: Tom Miller (CEO), Fred ManbyLaunched: 2020Headquarters: San Diego, CaliforniaFunding: $220 millionValuation: N/AKey Technologies: Artificial intelligence, cloud computing, deep neural networks/deep learning, generative AI, machine learning, robotics, quantum computingIndustry: BiotechPrevious appearances on Disruptor 50 list: 0 It can take 10-15 years for today's biopharmaceutical companies to bring new drugs all the way through discovery and clinical trial. San Diego-based Iambic Therapeutics' AI-driven platform can accelerate the pace of drug discovery and development, enabling drug development in just a few years. The company has novel medications in its pipeline to treat breast cancer and other HER2 cancers, and recently formed a research collaboration with pharmaceutical giant Lundbeck for a small molecule therapeutic to treat migraines. By predicting how its new molecules will interact with human systems, Iambic's technology can also reduce the need for clinical trials. The company was originally called Entos, and was founded when CEO Thomas Miller, a theoretical chemist and professor at California Institute of Technology, teamed up with longtime collaborator Fred Manby. In its first iteration, the company worked on making better chemical predictions across many industries and worked with companies including Toyota and Procter & Gamble. But the founders saw applications for their work in what's called small molecule drug discovery. Small molecule drugs, often synthesized chemically, target specific proteins or cellular pathways. Iambic's platform for drug discovery is called Enchant. The company says it provides high-confidence predictions in data-poor situations, such as early-stage and clinical-stage drug programs. "(Cancer) is an area of huge need," Miller told an interviewer for the California Institute of Technology in 2022. "It's an incredibly fast, quickly advancing disease. Many people are afflicted by it. There's many varieties of it. It is the combination of those things that means that if you have the ability to design a new drug, there's a way to … have a relatively fast timescale to advance that to the point where it's in human trials." Rather than selling its drug-discovery services and software to pharmaceutical companies, Iambic has focused on producing its own drugs. "Instead of running around, trying to convince people that this software is so great, and they should buy it, you can actually just use it and execute with it, and actually make better molecules. Then those molecules can stand on their own two feet," Miller said. In 2024, Iambic completed a B round of funding, with investors including OrbiMed, Nvidia and Sequoia Capital, and announced a collaboration with Nvidia, which has been teaming up as a venture investor with many startups across sectors using AI, including, for example, agtech Disruptor Carbon Robotics. Iambic also moved into a new headquarters in San Diego last year and took its headcount to about 100, enabling the company to run experiments on thousands of newly discovered molecules each week. It also announced an update to NeuralPLexer, which predicts protein-ligand structures, and published data in Nature Machine Intelligence showing that NeuralPLexer outperformed AlphaFold, the Nobel Prize in Chemistry winner developed by Google's DeepMind. Iambic also hired its first CFO, Michael Secora, who previously worked at publicly held Recursion.
